サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1744808

中咽頭がんの診断と治療法の世界市場

Oropharyngeal Cancer Diagnosis and Therapeutics

出版日
ページ情報
英文 395 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.08円
中咽頭がんの診断と治療法の世界市場
出版日: 2025年06月06日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 395 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

中咽頭がんの診断と治療法の世界市場は2030年までに30億米ドルに到達

2024年に19億米ドルと推定される中咽頭がんの診断と治療法の世界市場は、分析期間2024-2030年にCAGR 8.3％で成長し、2030年には30億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである内視鏡検査は、CAGR 10.2％を記録し、分析期間終了時には8億5,970万米ドルに達すると予測されています。生検セグメントの成長率は、分析期間でCAGR 9.6％と推定されます。

米国市場は5億1,440万米ドルと推定、中国はCAGR13.2％で成長予測

米国の中咽頭がんの診断と治療法市場は、2024年に5億1,440万米ドルと推定されます。世界第2位の経済大国である中国は、分析期間2024-2030年のCAGRを13.2%として、2030年までに6億6,700万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.1%と8.0%と予測されています。欧州では、ドイツがCAGR 5.5%で成長すると予測されています。

世界の中咽頭がんの診断と治療法市場- 主要動向と促進要因のまとめ

HPV関連がんの増加は中咽頭腫瘍の診断と治療の優先順位を再構築するか？

口腔咽頭がんは、舌根部、扁桃腺、咽頭壁を含む喉の中央部を侵す悪性腫瘍であるが、ヒトパピローマウイルス（HPV）関連症例の増加により、疫学的に大きな変化が起きています。歴史的にはタバコやアルコールの使用と関連していたが、現在では高所得国における新たな中咽頭がん症例の70％以上がHPV-16感染に起因しています。このような疾患の病因の変化は、患者の属性を変化させ、より若く、より健康で、男性に偏っており、診断プロトコールと治療戦略の再構築を促しています。

HPV陽性の腫瘍は、HPV陰性の腫瘍と比較して、独特の生物学的挙動を示し、治療に対する反応性が高いことが多いです。その結果、臨床医はp16免疫組織化学（IHC）やHPV DNA/RNA検査を標準的な診断ワークフローに組み込んで、バイオマーカー主導型の診断を受け入れています。早期発見は、PET-CTや狭帯域内視鏡などの高度な画像診断技術によってさらにサポートされ、腫瘍の広がりや転移リンパ節をより明瞭に描出することができます。これらのツールは、微細針吸引細胞診とともに、病期分類の精度を向上させ、患者サブグループ全体の治療計画に影響を及ぼしています。

なぜ集学的治療アプローチと脱増悪戦略が台頭しているのか？

中咽頭がんの治療方針は、腫瘍学的コントロールと発声、嚥下、QOLの維持のバランスをとる必要性を反映して、ますます個別化されてきています。標準的な治療法としては、放射線療法、化学療法、ロボットやレーザーを用いた経口腔的外科的切除があります。予後が良好なHPV陽性患者では、生存率を低下させることなく治療関連の罹患率を抑えるために、放射線照射量の減量、化学療法の省略、低侵襲手術などの治療強化解除戦略が臨床試験で積極的に評価されています。

一方、免疫療法は再発・転移症例に対する有望な選択肢として浮上しています。PD-1を標的とする免疫チェックポイント阻害剤（例えば、ペムブロリズマブ、ニボルマブ）は、プラチナ製剤不応患者において生存利益を示し、進行性疾患に対する治療経路を再構築しつつあります。放射線、ワクチン、標的療法を組み合わせたアプローチも、耐性サブタイプにおける奏効率を改善するために研究されています。このような進歩は、中咽頭がんの治療において、一般的な細胞毒性レジメンから分子誘導精密腫瘍学へのシフトが進んでいることを強調しています。

検診イニシアチブ、ワクチン接種プログラム、啓発キャンペーンは市場力学をどのように変化させているか？

HPVワクチン接種が世界的に重要視されるようになってきており、特に青少年や若年成人の間で、HPVに起因する中咽頭がんの発生率を減少させる上で、長期的なゲームチェンジャーとなっています。オーストラリア、英国、米国などの国家的な予防接種プログラムは、すでにHPV感染率と早期前がん病変の減少を実証しています。このような努力は、HPVと中咽頭がんとの関連についての一般市民の意識の高まりと相まって、早期の健康増進行動を促し、診断プールを拡大しています。

口腔咽頭がんのスクリーニング戦略は標準化されていないもの、唾液バイオマーカー、光学的画像診断ツール、機械学習支援型パターン認識などの利用により、高リスク集団で普及しつつあります。さらに、デジタルヘルス・キャンペーンやサバイバーシップ・イニシアチブは、集学的ケアコーディネーション、治療プロトコルの遵守、治療後のリハビリテーションを促進することで、患者の転帰を改善しています。

中咽頭がんの診断と治療法の世界市場を牽引しているのは？

中咽頭がんの診断と治療法市場の成長は、HPV関連がんの負担増、早期発見による生存率の向上、オーダーメイド治療レジメンの進化によってもたらされます。主要な促進要因は、分子診断と精密治療パラダイムの採用の増加であり、強固な臨床試験パイプラインと標的治療薬のFDA/EMA承認に支えられています。また、臓器温存戦略への動向は、低侵襲手術ツールや画像誘導療法に対する手術需要を拡大しています。

さらに、保険適用範囲の拡大、新興国における腫瘍学インフラの成長、HPV検査や免疫療法に対する有利な償還により、中咽頭がん治療がより身近なものとなっています。学術連携、ビッグデータ解析、AIベースの診断モデリングは、予測精度と臨床的意思決定を強化しています。

認知度、検診、技術の高度化が世界的に進むにつれて、市場は臨床需要の拡大と腫瘍学イノベーションへの機関投資の両方から恩恵を受けることになります。HPVワクチン接種、次世代診断、免疫腫瘍学の融合は、中咽頭がんを取り巻く環境の軌跡を形成し続けると思われます。

セグメント

タイプ（内視鏡、生検、画像診断、MRIスキャン、CTスキャン、PET-CTスキャン）、治療（手術、化学療法、放射線療法、標的療法、その他の治療）、エンドユーザー（病院エンドユーザー、外来手術センターエンドユーザー、その他のエンドユーザー）

調査対象企業の例（合計 47注目の企業）

  • AB Science
  • Advaxis Inc.
  • ALX Oncology
  • AstraZeneca plc
  • Bayer AG
  • Boston Biomedical Inc.
  • Bristol-Myers Squibb Co.
  • Debiopharm
  • GE Healthcare
  • Immunovaccine Inc.
  • Inovio Pharmaceuticals Inc.
  • Jaguar Health Inc.
  • Kovina Therapeutics
  • Merck & Co., Inc.
  • Nanobiotix
  • Novartis AG
  • Pacylex Pharmaceuticals Inc.
  • PNP Therapeutics Inc.
  • Synta Pharmaceuticals Corp.
  • Transgene S.A.

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、人為的な売上原価の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

Global Industry Analystsは、世界の主要なチーフ・エコノミスト（1万4,949人）、シンクタンク（62団体）、貿易・産業団体（171団体）の専門家の意見に熱心に従いながら、エコシステムへの影響を評価し、新たな市場の現実に対処しています。あらゆる主要国の専門家やエコノミストが、関税とそれが自国に与える影響についての意見を追跡調査しています。

Global Industry Analystsは、この混乱が今後2-3ヶ月で収束し、新しい世界秩序がより明確に確立されると予想しています。Global Industry Analystsは、これらの開発をリアルタイムで追跡しています。

2025年4月：交渉フェーズ

4月のリリースでは、世界市場全体に対する関税の影響を取り上げ、地域別の市場調整について紹介します。当社の予測は、過去のデータと進化する市場影響要因に基づいています。

2025年7月：最終関税リセット

お客様には、各国間で最終リセットが発表された後、7月に無料アップデート版をお届けします。最終アップデート版には、明確に定義された関税影響分析が組み込まれています。

相互および二国間貿易と関税の影響分析：

アメリカ <>中国<>メキシコ <>カナダ <>EU <>日本<>インド <>その他176カ国

業界をリードするエコノミスト：Global Industry Analystsの知識ベースは、国家、シンクタンク、貿易・業界団体、大企業、そして世界の計量経済状況におけるこの前例のないパラダイムシフトの影響を共有する領域の専門家など、最も影響力のあるチーフエコノミストを含む1万4,949人のエコノミストを追跡しています。当社の16,491を超えるレポートのほとんどは、マイルストーンに基づくこの2段階のリリーススケジュールを取り入れています。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP35467

Global Oropharyngeal Cancer Diagnosis and Therapeutics Market to Reach US$3.0 Billion by 2030

The global market for Oropharyngeal Cancer Diagnosis and Therapeutics estimated at US$1.9 Billion in the year 2024, is expected to reach US$3.0 Billion by 2030, growing at a CAGR of 8.3% over the analysis period 2024-2030. Endoscopy, one of the segments analyzed in the report, is expected to record a 10.2% CAGR and reach US$859.7 Million by the end of the analysis period. Growth in the Biopsy segment is estimated at 9.6% CAGR over the analysis period.

The U.S. Market is Estimated at US$514.4 Million While China is Forecast to Grow at 13.2% CAGR

The Oropharyngeal Cancer Diagnosis and Therapeutics market in the U.S. is estimated at US$514.4 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$667.0 Million by the year 2030 trailing a CAGR of 13.2% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.1% and 8.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.5% CAGR.

Global Oropharyngeal Cancer Diagnosis and Therapeutics Market - Key Trends & Drivers Summarized

Is the Rise in HPV-Linked Cancers Reshaping Diagnostic and Therapeutic Priorities for Oropharyngeal Tumors?

Oropharyngeal cancer, a malignancy affecting the middle part of the throat including the base of the tongue, tonsils, and pharyngeal walls, is undergoing a significant epidemiological shift driven by the increasing prevalence of human papillomavirus (HPV)-associated cases. While historically linked to tobacco and alcohol use, over 70% of new oropharyngeal cancer cases in high-income countries are now attributable to HPV-16 infection. This changing disease etiology is altering patient demographics-skewing younger, healthier, and male-and prompting a reconfiguration of diagnostic protocols and therapeutic strategies.

HPV-positive tumors exhibit distinct biological behavior and are often more responsive to treatment compared to their HPV-negative counterparts. Consequently, clinicians are embracing biomarker-driven diagnosis, incorporating p16 immunohistochemistry (IHC) and HPV DNA/RNA testing into standard diagnostic workflows. Early detection is further supported by advanced imaging techniques such as PET-CT and narrow-band endoscopy, enabling better delineation of tumor extent and metastatic nodes. These tools, along with fine-needle aspiration cytology, are improving staging accuracy and influencing treatment planning across patient subgroups.

Why Are Multimodal Treatment Approaches and De-Intensification Strategies Gaining Ground?

The therapeutic landscape for oropharyngeal cancer is increasingly personalized, reflecting the need to balance oncologic control with preservation of speech, swallowing, and quality of life. Standard therapies include radiation, chemotherapy, and transoral surgical resection using robotic or laser-assisted approaches. In HPV-positive patients with favorable prognosis, treatment de-intensification strategies-such as reduced radiation dosing, omission of chemotherapy, or minimally invasive surgery-are being actively evaluated in clinical trials to limit treatment-related morbidity without compromising survival outcomes.

Meanwhile, immunotherapy is emerging as a promising option for recurrent and metastatic cases. Immune checkpoint inhibitors targeting PD-1 (e.g., pembrolizumab, nivolumab) have demonstrated survival benefits in platinum-refractory patients and are reshaping therapeutic pathways for advanced disease. Combinatorial approaches with radiation, vaccines, and targeted therapies are also being explored to improve response rates in resistant subtypes. Such advancements underscore the growing shift from generalized cytotoxic regimens toward molecularly guided precision oncology in oropharyngeal cancer care.

How Are Screening Initiatives, Vaccination Programs, and Awareness Campaigns Changing Market Dynamics?

The growing global emphasis on HPV vaccination-particularly among adolescents and young adults-is a long-term game-changer in reducing the incidence of HPV-driven oropharyngeal cancers. National immunization programs in countries such as Australia, the U.K., and the U.S. are already demonstrating declining rates of HPV infection and early precancerous lesions. These efforts, combined with rising public awareness about HPV's link to oropharyngeal cancer, are catalyzing early health-seeking behavior and expanding the diagnostic pool.

Screening strategies, although not standardized for oropharyngeal cancer, are gaining traction in high-risk populations through the use of salivary biomarkers, optical imaging tools, and machine-learning-assisted pattern recognition. Additionally, digital health campaigns and survivorship initiatives are improving patient outcomes by fostering multidisciplinary care coordination, adherence to treatment protocols, and post-treatment rehabilitation.

What’s Driving the Global Market for Oropharyngeal Cancer Diagnosis and Therapeutics?

The growth in the oropharyngeal cancer diagnosis and therapeutics market is driven by a rising burden of HPV-associated cancers, improved survival rates due to early detection, and the evolution of tailored treatment regimens. A major growth driver is the increasing adoption of molecular diagnostics and precision treatment paradigms, supported by robust clinical trial pipelines and FDA/EMA approvals for targeted therapies. The trend toward organ-preserving strategies is also expanding procedural demand for minimally invasive surgical tools and image-guided therapies.

Further, expanding insurance coverage, growing oncology infrastructure in emerging economies, and favorable reimbursement for HPV testing and immunotherapy are making oropharyngeal cancer treatment more accessible. Academic collaborations, big data analytics, and AI-based diagnostic modeling are enhancing predictive accuracy and clinical decision-making.

As awareness, screening, and technological sophistication advance globally, the market is set to benefit from both growing clinical demand and institutional investment in oncology innovation. The convergence of HPV vaccination, next-gen diagnostics, and immune-oncology will continue to shape the trajectory of the oropharyngeal cancer landscape.

SCOPE OF STUDY:

The report analyzes the Oropharyngeal Cancer Diagnosis and Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Type (Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan, PET-CT Scan); Treatment (Surgery, Chemotherapy, Radiation Therapy, Targeted Therapy, Other Treatments); End-Use (Hospitals End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 47 Featured) -

  • AB Science
  • Advaxis Inc.
  • ALX Oncology
  • AstraZeneca plc
  • Bayer AG
  • Boston Biomedical Inc.
  • Bristol-Myers Squibb Co.
  • Debiopharm
  • GE Healthcare
  • Immunovaccine Inc.
  • Inovio Pharmaceuticals Inc.
  • Jaguar Health Inc.
  • Kovina Therapeutics
  • Merck & Co., Inc.
  • Nanobiotix
  • Novartis AG
  • Pacylex Pharmaceuticals Inc.
  • PNP Therapeutics Inc.
  • Synta Pharmaceuticals Corp.
  • Transgene S.A.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA <> CHINA <> MEXICO <> CANADA <> EU <> JAPAN <> INDIA <> 176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

COMPLIMENTARY PREVIEW

Contact your sales agent to request an online 300+ page complimentary preview of this research project. Our preview will present full stack sources, and validated domain expert data transcripts. Deep dive into our interactive data-driven online platform.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Tariff Impact on Global Supply Chain Patterns
    • Oropharyngeal Cancer Diagnosis and Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising HPV-Related Cancer Incidence Throws the Spotlight on Oropharyngeal Cancer Screening and Treatment
    • Advancements in Molecular Diagnostics Propel Growth in Precision Detection and Biomarker-Based Stratification
    • Expansion of Immunotherapy and Checkpoint Inhibitors Strengthens Business Case for Novel Therapeutic Modalities
    • Increased Adoption of Robotic Surgery and Laser Resection Drives Minimally Invasive Treatment Protocols
    • OEM Collaboration With Academic Research Institutions Spurs Pipeline Innovation and Clinical Trial Acceleration
    • Growing Availability of Saliva-Based and Non-Invasive Testing Enhances Patient Compliance and Early Detection
    • Surge in Public Awareness and HPV Vaccination Campaigns Promotes Preventive Oncology Approaches
    • Rising Global Head and Neck Cancer Burden Generates Demand for Region-Specific Diagnostic Guidelines
    • OEM Investment in AI-Enabled Imaging and Histopathology Tools Enhances Diagnostic Accuracy and Workflow Efficiency
    • Expansion of Genomic Sequencing in Oncology Supports Personalized Treatment Pathways for Oropharyngeal Cancer
    • Regulatory Fast-Track Approvals for Rare and Aggressive Variants Propel Innovation in Therapeutic Development
    • Increased Payer Support and Reimbursement for Immunotherapies Boosts Access in Developed Markets
    • OEM Emphasis on Companion Diagnostic Development Drives Precision Medicine in Targeted Therapy Applications
    • Growing Use of Telehealth in Oncology Follow-Up Care Expands Access to Diagnostic Consultations
    • OEM Advances in Radiomic and Multi-Omic Data Integration Strengthen Predictive Treatment Models
    • Global Initiatives for Cancer Care Equity Support Access to Diagnostic and Therapeutic Infrastructure in LMICs
    • Rising Demand for Integrated Care Pathways Encourages Cross-Specialty Collaboration in Cancer Management
    • OEM Focus on Real-World Evidence and Longitudinal Data Enhances Post-Market Surveillance of Cancer Drugs
    • Expansion of Patient Advocacy and Screening Awareness Campaigns Drives Diagnostic Volumes in At-Risk Populations
    • Challenges in Early Symptom Recognition Propel Demand for Primary Care-Based Screening Tools
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Oropharyngeal Cancer Diagnosis and Therapeutics Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Endoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Endoscopy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Endoscopy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Biopsy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Biopsy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Imaging by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Imaging by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for MRI Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for MRI Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for MRI Scan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for CT Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for CT Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for CT Scan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for PET-CT Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for PET-CT Scan by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for PET-CT Scan by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Targeted Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Targeted Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Treatments by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Treatments by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Surgery by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Surgery by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Chemotherapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Chemotherapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Radiation Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Radiation Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 38: World Recent Past, Current & Future Analysis for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 39: World Historic Review for Hospitals End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: World 15-Year Perspective for Hospitals End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 41: World Recent Past, Current & Future Analysis for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 42: World Historic Review for Ambulatory Surgery Centers End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: World 15-Year Perspective for Ambulatory Surgery Centers End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 44: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 45: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: World 15-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 47: USA Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: USA Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: USA 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 50: USA Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: USA Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: USA 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 53: USA Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: USA Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: USA 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 56: Canada Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Canada Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Canada 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 59: Canada Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Canada Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Canada 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 62: Canada Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Canada Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Canada 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • JAPAN
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 65: Japan Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: Japan Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: Japan 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 68: Japan Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Japan Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: Japan 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 71: Japan Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Japan Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Japan 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • CHINA
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 74: China Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: China Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: China 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 77: China Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: China Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: China 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 80: China Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: China Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: China 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • EUROPE
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 86: Europe Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Europe Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: Europe 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 89: Europe Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Europe Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Europe 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 92: Europe Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Europe Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Europe 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • FRANCE
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 95: France Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: France Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: France 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 98: France Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: France Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: France 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 101: France Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: France Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: France 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • GERMANY
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 104: Germany Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Germany Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Germany 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 107: Germany Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Germany Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Germany 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 110: Germany Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Germany Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Germany 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 113: Italy Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Italy Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Italy 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 116: Italy Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Italy Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Italy 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 119: Italy Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Italy Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Italy 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 122: UK Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: UK Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: UK 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 125: UK Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: UK Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: UK 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 128: UK Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: UK Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: UK 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 131: Spain Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Spain Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: Spain 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 134: Spain Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Spain Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Spain 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 137: Spain Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Spain Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Spain 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 140: Russia Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Russia Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Russia 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 143: Russia Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Russia Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Russia 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 146: Russia Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Russia Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Russia 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 149: Rest of Europe Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Rest of Europe Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Rest of Europe 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 152: Rest of Europe Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Rest of Europe Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Rest of Europe 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 155: Rest of Europe Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Rest of Europe Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Rest of Europe 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 161: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Asia-Pacific Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Asia-Pacific 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 164: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Asia-Pacific Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Asia-Pacific 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 167: Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Asia-Pacific Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Asia-Pacific 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 170: Australia Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Australia Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Australia 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 173: Australia Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Australia Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Australia 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 176: Australia Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Australia Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Australia 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • INDIA
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 179: India Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: India Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: India 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 182: India Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: India Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: India 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 185: India Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: India Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: India 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 188: South Korea Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: South Korea Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: South Korea 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 191: South Korea Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: South Korea Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: South Korea 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 194: South Korea Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: South Korea Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: South Korea 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 197: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Rest of Asia-Pacific Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Rest of Asia-Pacific 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 200: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Rest of Asia-Pacific Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: Rest of Asia-Pacific 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 203: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Asia-Pacific Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Asia-Pacific 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 209: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Latin America Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Latin America 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 212: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Latin America Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Latin America 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 215: Latin America Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Latin America Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Latin America 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 218: Argentina Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Argentina Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 220: Argentina 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 221: Argentina Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Argentina Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 223: Argentina 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 224: Argentina Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Argentina Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 226: Argentina 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 227: Brazil Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Brazil Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 229: Brazil 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 230: Brazil Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Brazil Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 232: Brazil 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 233: Brazil Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Brazil Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 235: Brazil 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 236: Mexico Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Mexico Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 238: Mexico 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 239: Mexico Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Mexico Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 241: Mexico 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 242: Mexico Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Mexico Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 244: Mexico 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 245: Rest of Latin America Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 246: Rest of Latin America Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 247: Rest of Latin America 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 248: Rest of Latin America Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Rest of Latin America Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 250: Rest of Latin America 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 251: Rest of Latin America Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Rest of Latin America Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 253: Rest of Latin America 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 257: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Middle East Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 259: Middle East 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 260: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Middle East Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 262: Middle East 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 263: Middle East Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Middle East Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 265: Middle East 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 266: Iran Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Iran Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 268: Iran 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 269: Iran Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Iran Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 271: Iran 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 272: Iran Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Iran Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 274: Iran 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 275: Israel Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Israel Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 277: Israel 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 278: Israel Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Israel Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 280: Israel 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 281: Israel Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Israel Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 283: Israel 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 284: Saudi Arabia Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 285: Saudi Arabia Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 286: Saudi Arabia 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 287: Saudi Arabia Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 288: Saudi Arabia Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 289: Saudi Arabia 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 290: Saudi Arabia Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 291: Saudi Arabia Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 292: Saudi Arabia 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 293: UAE Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 294: UAE Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 295: UAE 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 296: UAE Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 297: UAE Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 298: UAE 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 299: UAE Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 300: UAE Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 301: UAE 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 302: Rest of Middle East Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Rest of Middle East Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 304: Rest of Middle East 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 305: Rest of Middle East Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Rest of Middle East Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 307: Rest of Middle East 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 308: Rest of Middle East Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Rest of Middle East Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 310: Rest of Middle East 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030
  • AFRICA
    • Oropharyngeal Cancer Diagnosis and Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 311: Africa Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 312: Africa Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 313: Africa 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Type - Percentage Breakdown of Value Sales for Endoscopy, Biopsy, Imaging, MRI Scan, CT Scan and PET-CT Scan for the Years 2015, 2025 & 2030
    • TABLE 314: Africa Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 315: Africa Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 316: Africa 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by Treatment - Percentage Breakdown of Value Sales for Targeted Therapy, Other Treatments, Surgery, Chemotherapy and Radiation Therapy for the Years 2015, 2025 & 2030
    • TABLE 317: Africa Recent Past, Current & Future Analysis for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 318: Africa Historic Review for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 319: Africa 15-Year Perspective for Oropharyngeal Cancer Diagnosis and Therapeutics by End-Use - Percentage Breakdown of Value Sales for Hospitals End-Use, Ambulatory Surgery Centers End-Use and Other End-Uses for the Years 2015, 2025 & 2030

IV. COMPETITION